AMN
AMN Healthcare Services, Inc.
Medical - Care Facilities
Market Cap$811M
5Y Perf.-52.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AMN vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1721.78T
5Y Perf.-58.6%
AMN vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AMN | DBVT |
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $811M | $1721.78T |
| Revenue (TTM) | $2.73B | $0.00 |
| Net Income (TTM) | $-96M | $-168M |
| Gross Margin | 25.7% | — |
| Operating Margin | -3.5% | — |
| Forward P/E | 10.3x | — |
| Total Debt | $803M | $22M |
| Cash & Equiv. | $34M | $194M |
AMN vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AMN
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 100 | 47.3 | -52.7% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMN vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AMN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AMN
AMN Healthcare Services, Inc.
The Income Pick
AMN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.08
- Rev growth -8.5%, EPS growth 35.6%, 3Y rev CAGR -19.5%
- -44.1% 10Y total return vs DBVT's -86.8%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality and momentum.
- 0.3% margin vs AMN's -3.5%
- +114.1% vs AMN's +7.1%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AMN | -8.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs AMN's -3.5% |
| Stability / Safety | AMN | Beta 1.08 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +114.1% vs AMN's +7.1% |
| Efficiency (ROA) | AMN | -4.3% ROA vs DBVT's -89.0% |
AMN vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
AMN vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAMNLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
AMNAMN Healthcare Servic…
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AMN1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AMN5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
AMN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AMN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AMN and DBVT operate at a comparable scale, with $2.7B and $0 in trailing revenue.
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $2.7B | $0 |
| EBITDAEarnings before interest/tax | $62M | -$112M |
| Net IncomeAfter-tax profit | -$96M | -$168M |
| Free Cash FlowCash after capex | $234M | -$151M |
| Gross MarginGross profit ÷ Revenue | +25.7% | — |
| Operating MarginEBIT ÷ Revenue | -3.5% | — |
| Net MarginNet income ÷ Revenue | -3.5% | — |
| FCF MarginFCF ÷ Revenue | +8.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | +91.5% |
AMN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — AMN and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $811M | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | -8.46x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.31x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 8.33x | — |
| Price / SalesMarket cap ÷ Revenue | 0.30x | — |
| Price / BookPrice ÷ Book value/share | 1.26x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 3.47x | — |
Evenly matched — AMN and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
AMN leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
AMN delivers a -14.7% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.25x. On the Piotroski fundamental quality scale (0–9), AMN scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -14.7% | -130.2% |
| ROA (TTM)Return on assets | -4.3% | -89.0% |
| ROICReturn on invested capital | +1.6% | — |
| ROCEReturn on capital employed | +2.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 1.25x | 0.13x |
| Net DebtTotal debt minus cash | $769M | -$172M |
| Cash & Equiv.Liquid assets | $34M | $194M |
| Total DebtShort + long-term debt | $803M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -1.22x | -189.82x |
AMN leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,344 today (with dividends reinvested), compared to $2,366 for AMN. Over the past 12 months, DBVT leads with a +114.1% total return vs AMN's +7.1%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs AMN's -38.5% — a key indicator of consistent wealth creation.
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +38.7% | +5.5% |
| 1-Year ReturnPast 12 months | +7.1% | +114.1% |
| 3-Year ReturnCumulative with dividends | -76.8% | +20.4% |
| 5-Year ReturnCumulative with dividends | -76.3% | -66.6% |
| 10-Year ReturnCumulative with dividends | -44.1% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -38.5% | +6.4% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
AMN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMN is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMN currently trades 88.4% from its 52-week high vs DBVT's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 1.26x |
| 52-Week HighHighest price in past year | $23.74 | $26.18 |
| 52-Week LowLowest price in past year | $14.87 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +88.4% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 839K | 253K |
AMN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AMN as "Buy" and DBVT as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 7.3% for AMN (target: $23).
| Metric | AMNAMN Healthcare Se… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $22.50 | $46.33 |
| # AnalystsCovering analysts | 17 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AMN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 1 (Total Returns). 1 tied.
Best OverallAMN Healthcare Services, In… (AMN)Leads 3 of 6 categories
Loading custom metrics...
AMN vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is AMN or DBVT a better buy right now?
Analysts rate AMN Healthcare Services, Inc.
(AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMN or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -66. 6%, compared to -76. 3% for AMN Healthcare Services, Inc. (AMN). Over 10 years, the gap is even starker: AMN returned -44. 1% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMN or DBVT?
By beta (market sensitivity over 5 years), AMN Healthcare Services, Inc.
(AMN) is the lower-risk stock at 1. 08β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 16% more volatile than AMN relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 125% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AMN or DBVT?
On earnings-per-share growth, the picture is similar: AMN Healthcare Services, Inc.
grew EPS 35. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMN or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -3. 5% for AMN Healthcare Services, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMN leads at 1. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — AMN leads at 22. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AMN or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 130.
5% to $46. 33.
07Which pays a better dividend — AMN or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is AMN or DBVT better for a retirement portfolio?
For long-horizon retirement investors, AMN Healthcare Services, Inc.
(AMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08)). Both have compounded well over 10 years (AMN: -44. 1%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AMN and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.